XPhyto Therapeutics Corp. (CNSX:XPHY) s signed a definitive agreement to acquire 3A-Diagnostics GmbH for ?3.9 million on July 20, 2021. As per the agreement, ?0.4 million will be paid immediately and remaining ?3.5 million will be paid closing, planned for on or around October 31, 2021. XPhyto Therapeutics launched a non-brokered private placement of up to 5 million common shares of XPhyto Therapeutics at a price of $1.00 per Share for total gross proceeds of up to $5 million and up to $2.5 million of unsecured convertible debentures and 2 million common share purchase warrants. XPhyto Therapeutics intends to use the net proceeds of the Offering and Debentures for research and development, inventory purchases, general working capital purposes, and to complete the acquisition of 3a. Further to the acquisition agreement between XPhyto and 3a, the parties have agreed to extend the closing terms which is expected to complete on or around December 1, 2021. XPhyto Therapeutics Corp. (CNSX:XPHY) completed the acquisition of 3a-diagnostics GmbH on December 6, 2021.